title: A phase I trial of a new antiemetic drug--clebopride malate--in cisplatin-treated patients.
abstract: Clebopride, a new benzamide derivative, has, in common with the other members of this group, antidopaminergic activity. In animals, its therapeutic ratio is superior to that of metoclopramide at doses free of side effects associated with hyperprolactinemia and extrapyramidal symptoms. The present study was designed to define the maximum tolerated dose (MTD) in patients with advanced histologically-proven cancer, treated with cisplatin at a dose of greater than 50 mg/m2. Most of them were pretreated and refractory to standard antiemetics. Clebopride was started at a dosage of 0.10 mg/kg in a group of 6 patients and escalated by 0.2 mg at each dose level. A total of 30 patients were included. Side effects include somnolence, diarrhea and extrapyramidal-like symptoms. The latter occurred at almost all dose levels in 14% of the cycles and limited continuation of the study. Activity in this group of patients was encouraging but, considering the rate of extrapyramidal symptoms, further dose escalation is not indicated and activity at lower, nontoxic levels should be investigated.
authors.affiliation: Service de Médecine Interne et Laboratoire d'Investigation Clinique H.J. Tagnon, Unité de Gastroentérologie, Brussels, Belgium.
authors.forename: H
authors.initials: H
authors.lastname: Bleiberg
authors.forename: M
authors.initials: M
authors.lastname: Piccart
authors.forename: S
authors.initials: S
authors.lastname: Lips
authors.forename: J M
authors.initials: JM
authors.lastname: Panzer
authors.forename: J B
authors.initials: JB
authors.lastname: N'Koua Mbon
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D009369:Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D001549:Benzamides; C014417:clebopride; D002945:Cisplatin